Nothing Special   »   [go: up one dir, main page]

BR112015008200A2 - derivados de imidazopiridina - Google Patents

derivados de imidazopiridina

Info

Publication number
BR112015008200A2
BR112015008200A2 BR112015008200A BR112015008200A BR112015008200A2 BR 112015008200 A2 BR112015008200 A2 BR 112015008200A2 BR 112015008200 A BR112015008200 A BR 112015008200A BR 112015008200 A BR112015008200 A BR 112015008200A BR 112015008200 A2 BR112015008200 A2 BR 112015008200A2
Authority
BR
Brazil
Prior art keywords
lower alkyl
disorder
halogen
disease
cyano
Prior art date
Application number
BR112015008200A
Other languages
English (en)
Inventor
Wichmann Juergen
Jagasia Ravi
Jakob-Roetne Roland
M Ceccarelli Simona
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR112015008200A2 publication Critical patent/BR112015008200A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

resumo patente de invenção: "derivados de imidazopiridina". a presente invenção refere-se aos compostos de fórmula geral (i), i em que ar é fenila ou piridinila; x1 é n ou ch, x2 é n ou ch, com a condição que somente um de x1 ou x2 seja n e o outro seja ch; r1 é hidrogênio, halogênio, alquila inferior, alcóxi inferior, alquila inferior substituída por halogênio, ciano ou s(o)2-alquila inferior; r2 é hidrogênio, halogênio, alquila inferior, alcóxi inferior, alquila inferior substituída por halogênio ou ciano; n é 1 ou 2; ou a um sal de adição ácido farmaceuticamente aceitável, a uma mistura racêmica ou ao seu enantiômero correspondente e/ou isômeros ópticos deles. os compostos podem ser usados para o tratamento de esquizofrenia, distúrbio obsessivo-compulsivo de personalidade, depressão maior, distúrbios bipolares, distúrbios de ansiedade, envelhecimento normal, epilepsia, degeneração da retina, lesão traumática do cérebro, lesão da medula espinhal, distúrbio de estresse pós-traumático, distúrbio do pânico, doença de parkinson, demência, doença de alzheimer, deterioração cognitiva moderada, disfunção cognitiva induzida por quimioterapia, síndrome de down, distúrbios do espectro autista, perda de audição, zumbido no ouvido, ataxia espinocerebelar, esclerose lateral amiotrófica, esclerose múltipla, doença de huntington, acidente vascular cerebral, terapia de radiação, estresse crônico, abuso de drogas neuroativas, tais como o álcool, os narcóticos, a metanfetamina, a fenciclidina e a cocaína.
BR112015008200A 2012-11-29 2013-11-26 derivados de imidazopiridina BR112015008200A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12194721 2012-11-29
PCT/EP2013/074662 WO2014082979A1 (en) 2012-11-29 2013-11-26 Imidazopyridine derivatives

Publications (1)

Publication Number Publication Date
BR112015008200A2 true BR112015008200A2 (pt) 2017-07-04

Family

ID=47263164

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015008200A BR112015008200A2 (pt) 2012-11-29 2013-11-26 derivados de imidazopiridina

Country Status (11)

Country Link
US (1) US9315502B2 (pt)
EP (1) EP2925756B1 (pt)
JP (1) JP6007339B2 (pt)
KR (1) KR101735975B1 (pt)
CN (1) CN104822679B (pt)
BR (1) BR112015008200A2 (pt)
CA (1) CA2884956A1 (pt)
HK (1) HK1208029A1 (pt)
MX (1) MX2015006513A (pt)
RU (1) RU2644949C2 (pt)
WO (1) WO2014082979A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012177647A2 (en) 2011-06-20 2012-12-27 Kerry Lane Mycotoxin diagnostics and methods thereof
WO2015200341A1 (en) * 2014-06-23 2015-12-30 Dr. Reddy's Laboratories Ltd. Substituted imidazo[1,2-a]pyridine compounds useful for the treatment of pain
WO2018013430A2 (en) 2016-07-12 2018-01-18 Arisan Therapeutics Inc. Heterocyclic compounds for the treatment of arenavirus infection

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002002557A2 (en) * 2000-06-30 2002-01-10 Neurogen Corporation 2-phenylimidazo[1,2-a]pyridine derivatives: a new class of gaba brain receptor ligands
DOP2006000051A (es) * 2005-02-24 2006-08-31 Lilly Co Eli Inhibidores de vegf-r2 y métodos
EP1861095A1 (en) * 2005-03-24 2007-12-05 Glaxo Group Limited Derivatives of imidazo(1,2-a)pyridine useful as medicaments for treating gastrointestinal diseases
KR101062583B1 (ko) * 2006-01-17 2011-09-06 에프. 호프만-라 로슈 아게 Ｇａｂａ 수용체에 의해 알츠하이머병의 치료에 유용한아릴-아이속사졸-4-일-이미다조[1,2-ａ]피리딘
WO2008016123A1 (fr) * 2006-08-03 2008-02-07 Takeda Pharmaceutical Company Limited INHIBITEUR DE LA GSK-3β
FR2906250B1 (fr) * 2006-09-22 2008-10-31 Sanofi Aventis Sa Derives de 2-aryl-6phenyl-imidazo(1,2-a) pyridines, leur preparation et leur application en therapeutique
CN101679408B (zh) * 2006-12-22 2016-04-27 Astex治疗学有限公司 作为fgfr抑制剂的双环杂环化合物
JP2010516672A (ja) * 2007-01-22 2010-05-20 アストラゼネカ・アクチエボラーグ 新規なヘテロアリール置換されたイミダゾ［１，２−ａ］ピリジン誘導体
CN102224152B (zh) * 2008-11-20 2014-05-21 健泰科生物技术公司 吡唑并吡啶pi3k抑制剂化合物及使用方法

Also Published As

Publication number Publication date
JP2016500121A (ja) 2016-01-07
WO2014082979A1 (en) 2014-06-05
CN104822679B (zh) 2016-10-19
RU2015120651A (ru) 2017-01-10
EP2925756B1 (en) 2017-02-01
CN104822679A (zh) 2015-08-05
KR101735975B1 (ko) 2017-05-15
US20150259341A1 (en) 2015-09-17
JP6007339B2 (ja) 2016-10-12
EP2925756A1 (en) 2015-10-07
HK1208029A1 (en) 2016-02-19
US9315502B2 (en) 2016-04-19
RU2644949C2 (ru) 2018-02-15
CA2884956A1 (en) 2014-06-05
MX2015006513A (es) 2015-08-14
KR20150076250A (ko) 2015-07-06

Similar Documents

Publication Publication Date Title
BR112015004942A2 (pt) benzimidazóis como agentes ativos do snc
MX362532B (es) Derivados de 1,7-naftiridina.
MX2016008842A (es) Derivados de n-fenil-lactama capaces de estimular la neurogenesis y su uso en el tratamiento de trastornos neurologicos.
AR096640A1 (es) Derivados de indolin-2-ona o pirrolo-piridin / pirimidin-2-ona
AR093576A1 (es) Derivados heterociclicos sustituidos
BR112015027362A2 (pt) derivados de isoquinolina estimulantes de neurogênese
BR112017022568A2 (pt) compostos e seus usos como inibidores de bace1
BR112015011094A2 (pt) 1,6-naftiridinas substituídas
EA201590406A1 (ru) Мочевинные и амидные производные аминоалкилпиперазинов и их применение
AR106588A1 (es) Derivados de indolin-2-ona para el tratamiento de enfermedades del snc
BR112015008200A2 (pt) derivados de imidazopiridina
BR112014029478A2 (pt) profármaco de aminoácido contendo flúor
PH12016500605A1 (en) Pyrido[4,3-b]pyrazine-2-carboxamides as neurogenic agents for the treatment of neurodegenerative disorders
AR079103A1 (es) Compuesto de sal de mesilato de (s) -2-(4-(3-fluoro-benciloxi)-bencilamino)-propionamida, forma polimorfica (nf6) , composicion farmaceutica, uso del mismo para la preparacion de un medicamento y su procesos de preparacion
BR112016017816A8 (pt) derivados de etinila, seus usos, e composição farmacêutica
BR112015000313A2 (pt) piperazino[1,2-a]indol-1-onas e [1,4]diazepino[1,2-a]indol-1-ona
MX2015013915A (es) Piperazino[1,2-a]indol-1-onas y [1,4]diazepino[1,2-a]indol-1-ona.
MX363461B (es) Derivados de benzisoxazol como moduladores de la neurogénesis y el uso de los mismos en el tratamiento de enfermedades neurológicas y trastornos neuropsiquiátricos.
MX2016001528A (es) Derivados de indol-carboxamida.
AR100532A1 (es) Derivados de indolín-2-ona y 1,3-dihidro-pirrolo[3,2-c]piridín-2-ona
TH167754A (th) ไพเพอราซิโน[1,2-a]อินดอล-1-โอนและ[1,4]ไดอะซีพิโน[1,2-a]อินดอล-1-โอน
TH165816B (th) ไพริโด[4,3-b]ไพราซีน-2-คาร์บอกซาไมด์ ในรูปสารก่อกำเนิดประสาทสำหรับ การรักษาความผิดปกติที่มีภาวะเสื่อมของระบบประสาท

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notice of approval relating to section 229 industrial property law
B15K Others concerning applications: alteration of classification

Free format text: A CLASSIFICACAO ANTERIOR ERA: C07D 471/04

Ipc: C07D 471/04 (2006.01), A61P 25/00 (2006.01), A61K

B06U Preliminary requirement: requests with searches performed by other patent offices: suspension of the patent application procedure
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 7A ANUIDADE.

B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements